BioSpace News Archive

Surge in initiatives by several government bodies to reduce the healthcare costs is projected to translate into extensive growth prospects for companies operating in the global long-term care software market during the forecast period between 2021 and 2031.

The increasing recurrence of outsourcing of R&D exercises by significant drug organizations to zero in on their center abilities is a high-sway rendering driver for market development.

Gemina Laboratories Ltd. is excited to announce the appointment of Brian Firth, an accomplished diagnostic industry executive, as the Company’s new Chief Executive Officer.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference.

TRACON Pharmaceuticals, Inc. announced entry into a $35 million non-dilutive long-term debt facility with Runway Growth Capital LLC, a leading provider of loans to venture and non-venture backed companies seeking non-dilutive capital.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that four abstracts for Arcutis’ topical roflumilast program in seborrheic dermatitis and psoriasis will be presented at European Academy of Dermatology and Venereology (EADV) Congress, held September 7-10, 2022, in Milan and virtually.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), today announced that two abstracts will be presented from the KER-012 and KER-050 programs at the American Society for Bone and Mineral Research (“ASBMR”) 2022 Annual Meeting.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be participating at the H.C. Wainwright 24th Global Investment Conference and Ladenburg Thalmann 2022 Healthcare Conference.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that the results from its Phase 2 clinical study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be featured in a proffered paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2022.